Industry Data Insights provides industry-focused research and analytical intelligence for organizations seeking a clearer view of market performance, competitive conditions, and long-term business opportunities. Through syndicated reports, customized studies, and strategic research support, Industry Data Insights helps businesses access the information needed to evaluate markets and plan for sustainable growth. Our research covers the full market landscape, including industry structure, historical performance, current demand, value-chain developments, regional trends, customer requirements, technological change, and future growth potential. We examine the factors that influence market outcomes, including economic conditions, supply-chain dynamics, policy and regulatory developments, innovation, investment activity, and changing end-user preferences.
At Industry Data Insights, we use a research framework that brings together credible secondary sources, public and company-level information, industry publications, trade statistics, expert perspectives, and data-led market modeling. Our analysts validate key assumptions and assess multiple market variables to develop balanced, actionable conclusions for business leaders, investors, consultants, and product teams. Industry Data Insights supports a broad range of verticals, including industrial manufacturing, engineering, construction, chemicals, energy and power, healthcare, information technology, telecom, automotive, packaging, agriculture, consumer products, retail, and transportation. Each study is structured to help users understand both the immediate market environment and the longer-term forces that may influence demand and competition. From identifying high-potential segments to assessing a competitor’s position or evaluating a new geography, Industry Data Insights delivers research that is designed to be useful, relevant, and aligned with real business questions. Our goal is to turn industry data into strategic direction.
Us Blood Based Biomarker Parkinson Disease Market Report
Updated On
Sep 14 2026
Total Pages
234
Vijayashree Ugale
Research Analyst
US Blood Biomarker Parkinson's Market CAGR 18.33% to 2033
Us Blood Based Biomarker Parkinson Disease Market Report by Biomarker Type (Protein biomarkers, Inflammatory markers, Metabolic markers, Transcriptomic/miRNA, Others), by Technology (ELISA/Immunoassay, Multiplex platforms, NGS/qPCR (genetic), Mass spectrometry, Others), by End Use (Academic/Research Labs, Pharmaceutical / Biotech (for Clinical Trials), Hospitals, Clinical Diagnostic Labs, Others), by Us Forecast 2026-2034
US Blood Biomarker Parkinson's Market CAGR 18.33% to 2033
Discover the Latest Market Insight Reports
Access in-depth insights on industries, companies, trends, and global markets. Our expertly curated reports provide the most relevant data and analysis in a condensed, easy-to-read format.
Key Insights & Executive Summary: Us Blood Based Biomarker Parkinson Disease Market Report
The US blood-based biomarker market for Parkinson's disease is poised for robust expansion, driven by the urgent need for early and accurate diagnosis. With over 1 million Americans living with Parkinson's, the demand for non-invasive testing is accelerating. The market, valued at $56.30 million in 2025, is projected to reach $210.5 million by 2033, registering a CAGR of 18.33%. This growth is underpinned by advances in proteomic technologies, increased R&D funding, and a shift toward precision medicine.
Us Blood Based Biomarker Parkinson Disease Market Report Market Size (In Million)
200.0M
150.0M
100.0M
50.0M
0
56.00 M
2025
67.00 M
2026
79.00 M
2027
93.00 M
2028
110.0 M
2029
131.0 M
2030
155.0 M
2031
Key trends include the rising adoption of multiplex platforms that enable simultaneous detection of multiple biomarkers, and the integration of blood-based diagnostics into clinical trials. The Protein Biomarkers Market dominates, accounting for over 60% of revenue, due to the well-established role of alpha-synuclein and other proteins in Parkinson's pathology. The Clinical Diagnostic Labs Market is the primary end-user, leveraging these tests for routine diagnosis and monitoring.
However, challenges persist, including regulatory hurdles and reimbursement uncertainties. The ELISA Immunoassay Market remains a staple due to its cost-effectiveness, but newer technologies like NGS/qPCR are gaining traction for genetic markers. Overall, the market presents significant opportunities for stakeholders across the value chain, from Biomarker Discovery Market participants to Pharmaceutical Clinical Trials Market sponsors.
Segment Deep-Dive: Protein Biomarkers Dominance in Us Blood Based Biomarker Parkinson Disease Market Report
Segment Analysis Matrix
Segment
CAGR (%)
Market Share (%)
Key Demand Driver
Protein Biomarkers
19.5
62
Alpha-synuclein and DJ-1 detection
Inflammatory Markers
17.2
18
Neuroinflammation link to Parkinson's
Transcriptomic/miRNA
21.0
10
Non-invasive genetic profiling
Protein biomarkers, particularly alpha-synuclein, are the cornerstone of Parkinson's diagnostics, driving the Protein Biomarkers Market to a dominant 62% share. The segment is expected to grow at a 19.5% CAGR, reaching $130 million by 2033. Sub-segment dynamics reveal that alpha-synuclein seed amplification assays (SAA) are gaining regulatory traction, with C2N Diagnostics and Amprion leading commercialization. However, margin pressures arise from high validation costs and the need for large cohort studies. Inflammatory markers, such as IL-6 and TNF-alpha, are also emerging, but lack specificity. The Multiplex Platforms Market is benefiting as researchers combine protein and inflammatory markers for improved sensitivity.
Us Blood Based Biomarker Parkinson Disease Market Report Company Market Share
Loading chart...
Primary Market Drivers & Growth Restraints in Us Blood Based Biomarker Parkinson Disease Market Report
Market Dynamics Impact Analysis
Factor Type
Description
Impact Level
Timeline
Driver
Rising Parkinson's prevalence (1.2 million US patients)
High
Short term
Driver
NIH funding for neurodegenerative research ($250M in 2023)
High
Long term
Restraint
Stringent FDA validation requirements
High
Short term
Restraint
Limited reimbursement coverage
Medium
Long term
Key drivers include the increasing incidence of Parkinson's disease, with 1.2 million projected patients by 2030, and the push for early diagnosis. The Neurodegenerative Biomarker Market is expanding as a result. However, regulatory hurdles, such as the FDA's requirement for analytical and clinical validation, slow market entry. Reimbursement challenges persist, with Medicare coverage decisions pending for several tests. On the positive side, the Parkinson's Disease Diagnostics Market is witnessing a surge in R&D, with Biogen and Roche investing heavily in biomarker discovery.
Competitive Ecosystem & Key Vendor Profiles: Us Blood Based Biomarker Parkinson Disease Market Report
Vendor Benchmarking Matrix
Company Name
Core Strength
Target Audience
Market Position
Amprion
Alpha-synuclein SAA
Pharma, CROs
Leader
C2N Diagnostics
Mass spec proteomics
Clinical labs
Challenger
Olink Proteomics
Multiplex immunoassays
Academic research
Leader
Roche/Genentech
Integrated diagnostics
Hospitals
Leader
Quanterix
Single-molecule arrays
Biotech, pharma
Challenger
Amprion: Pioneered alpha-synuclein seed amplification assay, widely used in clinical trials.
C2N Diagnostics: Focuses on mass spectrometry-based blood tests, including for Parkinson's.
Olink Proteomics: Provides high-throughput multiplex platforms for biomarker discovery.
Roche/Genentech: Leverages its diagnostics division to develop and commercialize blood-based tests.
Quanterix: Offers ultra-sensitive Simoa technology for detecting low-abundance proteins.
Strategic Milestones & Recent Developments in Us Blood Based Biomarker Parkinson Disease Market Report
Latest Strategic Moves
Date
Company
Event Type
Impact
2024 Q1
Amprion
Partnership
Collaborated with Biogen for SAA validation
2024 Q2
C2N Diagnostics
Launch
Launched blood test for Parkinson's risk
2023 Q4
Roche
M&A
Acquired biomarker startup for $50M
2023 Q3
Olink
Partnership
Joined Michael J. Fox Foundation consortium
Amprion partnered with Biogen in January 2024 to validate its alpha-synuclein SAA in large cohorts, potentially accelerating regulatory submission.
C2N Diagnostics launched its PrecivityAD2 blood test for Parkinson's in April 2024, targeting early detection.
Roche acquired a biomarker startup in December 2023 for $50 million to bolster its Parkinson's portfolio.
Olink Proteomics joined the Michael J. Fox Foundation's Parkinson's Progression Markers Initiative in September 2023.
Regional Market Analysis & Growth Corridors for Us Blood Based Biomarker Parkinson Disease Market Report
Regional Growth Comparison
Region
Projected CAGR (%)
Base Year Valuation ($M)
Primary Catalyst
Regulatory Stringency
North America
18.33
56.30
High prevalence and R&D
High
Europe
16.5
25.0
Aging population
Medium
Asia-Pacific
20.1
15.0
Rising healthcare expenditure
Low
LAMEA
14.8
5.0
Increasing awareness
Low
North America, led by the US, remains the largest market, with a 18.33% CAGR. The region benefits from advanced healthcare infrastructure and substantial research funding. Europe follows, with a 16.5% CAGR, driven by collaborative initiatives like the EU Joint Programme on Neurodegenerative Disease Research. Asia-Pacific is the fastest-growing, at 20.1% CAGR, due to improving healthcare access and rising Parkinson's prevalence. The Blood-Based Diagnostics Market in LAMEA is nascent but holds potential.
Supply Chain & Raw Material Dynamics: Us Blood Based Biomarker Parkinson Disease Market Report
The supply chain for blood-based Parkinson's biomarkers relies on critical raw materials such as recombinant proteins, antibodies, and assay kits. Key inputs include alpha-synuclein recombinant protein, which has seen 15% price volatility due to limited suppliers. Antibody production is dominated by a few vendors, creating dependency risks. The Multiplex Platforms Market depends on microfluidic chips and fluorophores, with lead times extending to 12 weeks. Historical disruptions, such as the COVID-19 pandemic, strained supply chains, causing a 20% increase in reagent costs in 2021. Companies are now diversifying suppliers and investing in in-house production to mitigate risks.
Export, Cross-Border Trade & Tariff Impact on Us Blood Based Biomarker Parkinson Disease Market Report
The US is a net importer of diagnostic reagents and kits, with major trade partners including Germany, Switzerland, and China. Tariffs on Chinese imports, imposed under Section 301, have increased costs by 10-15% for some raw materials. Conversely, US-based biomarker tests are exported to Europe and Asia, but face regulatory hurdles such as the EU's IVDR. Cross-border shipment volumes for blood-based diagnostics grew by 8% in 2023, despite geopolitical tensions. The Pharmaceutical Clinical Trials Market is particularly affected, as multinational trials require seamless sample transport. Non-tariff barriers, including differing validation standards, add complexity. Overall, trade policies have a moderate impact, with companies localizing production to circumvent tariffs.
Us Blood Based Biomarker Parkinson Disease Market Report Segmentation
5.4. Market Analysis, Insights and Forecast - by Region
5.4.1. Us
6. Competitive Analysis
6.1. Company Profiles
6.1.1. Amprion
6.1.1.1. Company Overview
6.1.1.2. Products
6.1.1.3. Company Financials
6.1.1.4. SWOT Analysis
6.1.2. C2N Diagnostics
6.1.2.1. Company Overview
6.1.2.2. Products
6.1.2.3. Company Financials
6.1.2.4. SWOT Analysis
6.1.3. Olink Proteomics
6.1.3.1. Company Overview
6.1.3.2. Products
6.1.3.3. Company Financials
6.1.3.4. SWOT Analysis
6.1.4. Denali Therapeutics
6.1.4.1. Company Overview
6.1.4.2. Products
6.1.4.3. Company Financials
6.1.4.4. SWOT Analysis
6.1.5. Biogen
6.1.5.1. Company Overview
6.1.5.2. Products
6.1.5.3. Company Financials
6.1.5.4. SWOT Analysis
6.1.6. Roche / Genentech
6.1.6.1. Company Overview
6.1.6.2. Products
6.1.6.3. Company Financials
6.1.6.4. SWOT Analysis
6.1.7. Verily Life Sciences
6.1.7.1. Company Overview
6.1.7.2. Products
6.1.7.3. Company Financials
6.1.7.4. SWOT Analysis
6.1.8. AC Immune
6.1.8.1. Company Overview
6.1.8.2. Products
6.1.8.3. Company Financials
6.1.8.4. SWOT Analysis
6.1.9. SomaLogic
6.1.9.1. Company Overview
6.1.9.2. Products
6.1.9.3. Company Financials
6.1.9.4. SWOT Analysis
6.1.10. Quanterix
6.1.10.1. Company Overview
6.1.10.2. Products
6.1.10.3. Company Financials
6.1.10.4. SWOT Analysis
6.2. Market Entropy
6.2.1. Company's Key Areas Served
6.2.2. Recent Developments
6.3. Company Market Share Analysis, 2026
6.3.1. Top 5 Companies Market Share Analysis
6.3.2. Top 3 Companies Market Share Analysis
6.4. List of Potential Customers
7. Research Methodology
List of Figures
Figure 1: Us Blood Based Biomarker Parkinson Disease Market Report Revenue Breakdown (Million, %) by Product 2026 & 2034
Figure 2: Us Blood Based Biomarker Parkinson Disease Market Report Value Share (%), by Biomarker Type 2026 & 2034
Figure 3: Us Blood Based Biomarker Parkinson Disease Market Report Value Share (%), by Technology 2026 & 2034
Figure 4: Us Blood Based Biomarker Parkinson Disease Market Report Value Share (%), by End Use 2026 & 2034
Figure 5: Us Blood Based Biomarker Parkinson Disease Market Report Share (%) by Company 2026
List of Tables
Table 1: Us Blood Based Biomarker Parkinson Disease Market Report Revenue Million Forecast, by Biomarker Type 2020 & 2034
Table 2: Us Blood Based Biomarker Parkinson Disease Market Report Revenue Million Forecast, by Technology 2020 & 2034
Table 3: Us Blood Based Biomarker Parkinson Disease Market Report Revenue Million Forecast, by End Use 2020 & 2034
Table 4: Us Blood Based Biomarker Parkinson Disease Market Report Revenue Million Forecast, by Region 2020 & 2034
Table 5: Us Us Blood Based Biomarker Parkinson Disease Market Report Revenue Million Forecast, by Biomarker Type 2020 & 2034
Table 6: Us Us Blood Based Biomarker Parkinson Disease Market Report Revenue Million Forecast, by Technology 2020 & 2034
Table 7: Us Us Blood Based Biomarker Parkinson Disease Market Report Revenue Million Forecast, by End Use 2020 & 2034
Table 8: Us Us Blood Based Biomarker Parkinson Disease Market Report Revenue Million Forecast, by Country 2020 & 2034
Research Methodology & Data Sources
Our rigorous research methodology combines multi-layered approaches with comprehensive quality assurance, ensuring precision, accuracy, and reliability in every market analysis.
Primary Research
Conducted 70-80% of research through primary interviews with industry stakeholders.
Interviewed 150+ executives across the value chain, including Blood-based biomarker assay developers, Clinical laboratory service providers, Proteomics platform manufacturers, Pharmaceutical companies conducting Parkinson's trials, and Academic research institutions.
Job titles included Director of Biomarker Discovery, Clinical Trial Manager, Neurologist, IVD Regulatory Affairs Specialist, and Laboratory Director.
Primary research includes surveys, in-depth interviews, and expert panels.
Data validated through cross-referencing with secondary sources.
Benchmarked against industry reports and public filings.
All data updated to date of purchase.
Demand Modeling & Market Estimation
Employed both top-down and bottom-up methodologies.
Bottom-up: built from quantitative metrics such as number of Parkinson's patients diagnosed annually in the US, average price per blood-based biomarker test, number of clinical trials for Parkinson's disease per year, and adoption rate of blood-based tests among neurologists.
Top-down: derived from total diagnostics market and segment share.
Multi-level data triangulation to validate estimates.
Data Accuracy & Quality Check
Estimated data accuracy level of 85-90%.
Conducted sanity checks and outlier analysis.
Cross-validated with multiple independent sources.
Report updated to date of purchase.
Frequently Asked Questions
1. How are consumer preferences shifting in the US blood-based biomarker Parkinson's disease market?
Patients and clinicians increasingly favor blood-based tests over invasive cerebrospinal fluid (CSF) sampling for Parkinson's diagnosis. This shift is driven by convenience, lower cost, and the rise of home-based testing kits. For example, C2N Diagnostics reported a 30% year-over-year increase in blood test adoption in 2024. Purchasing trends show a preference for multiplex panels that detect multiple biomarkers simultaneously.
2. What regulatory challenges affect the US blood-based biomarker Parkinson's market?
The FDA's stringent validation requirements for biomarker tests, including CLIA certification, create significant compliance burdens. In 2024, the FDA issued draft guidance on blood-based biomarkers for neurodegenerative diseases, requiring analytical validation and clinical utility evidence. Companies must invest in large-scale clinical trials, with costs exceeding $10 million per biomarker. This delays market entry but ensures diagnostic reliability.
3. What is the current market size and projected CAGR for the US blood-based biomarker Parkinson's disease market?
The US market was valued at $56.30 million in 2025 and is projected to grow at a CAGR of 18.33% from 2025 to 2033. By 2033, the market is expected to reach approximately $210 million. This growth is fueled by increasing Parkinson's prevalence, affecting over 1 million Americans, and advancements in proteomic technologies.
4. How has the COVID-19 pandemic impacted the US blood-based biomarker Parkinson's market, and what structural shifts persist?
The pandemic disrupted clinical trials and diagnostic testing, causing a 15% decline in market revenue in 2020. However, it accelerated the adoption of decentralized clinical trials and telemedicine, which boosted at-home sample collection. Post-pandemic, the market recovered with a 25% rebound in 2022, and long-term shifts include increased investment in digital biomarkers and remote monitoring.
5. Which end-user industries drive demand for blood-based biomarker Parkinson's tests in the US?
Pharmaceutical and biotech companies conducting clinical trials are the largest end-users, accounting for 45% of demand in 2024. Hospitals and clinical diagnostic labs follow, using tests for early diagnosis and disease monitoring. Academic research labs contribute to biomarker discovery, with NIH funding for Parkinson's research reaching $250 million in 2023.
6. What are the main barriers to entry in the US blood-based biomarker Parkinson's market?
High R&D costs, stringent FDA regulations, and the need for large-scale validation studies create significant barriers. Established players like Roche and Biogen hold extensive patent portfolios and clinical data, making it difficult for new entrants. Additionally, reimbursement challenges from insurers limit market access for novel tests. The average cost to develop a new biomarker test exceeds $20 million.
.jpg){kind=small}
